GDF 15 - a novel biomarker in the offing for heart failure

Current Cardiology Reviews

Volumn 12, Issue 1, 2016, Pages 37-46

  George, Melvin ^a   Jena, Amrita ^a   Srivatsan, Varsha ^a   Muthukumar, Rajaram ^a   Dhandapani, V E ^a  

^a SRM INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

All cause mortality; Cardiac biomarker; GDF 15; Heart failure; Novel biomarker; Prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYSTATIN C; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN P53; SMAD PROTEIN; BIOLOGICAL MARKER; GDF15 PROTEIN, HUMAN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTICLE; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; ELECTRONIC MEDICAL RECORD; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE INJURY; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MORTALITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SMOKING; SYSTEMATIC REVIEW; ANIMAL; BLOOD; PROGNOSIS;

ANIMALS; BIOMARKERS; GROWTH DIFFERENTIATION FACTOR 15; HEART FAILURE; HUMANS; PROGNOSIS;

EID: 84956919993     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/1573403X12666160111125304     Document Type: Article

References (44)

1. [1]. National heart failure audit. http://www.ucl.ac.uk/nicor/audits/heartfailure/additionalfiles/pdfs/annualreports/annual12.pdf. Accessed 27 Feb 2014
2. [2]. Mann DL. Management of Heart Failure with Reduced Ejection Fraction. In: Braunwald E. Heart disease: A textbook of Cardiovascular Medicine. 8thedn.Elsevier, New Delhi; 2008: 611-40.
3. [3]. Manhenke C, Ørn S, von Haehling S, et al. Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. Int J Cardiol 2013; 166: 729-35.
4. [4]. Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: 1810-52.
5. [5]. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-59.
6. [6]. Growth diffrentiation factor 15. http://www.ncbi.nlm.nih.gov/gene/9518. Accessed 27 Feb 2014
7. [7]. Xu J, Kimball TR, Lorenz JN, et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 2006; 98: 342-50.
8. [8]. Xu X, Li Z, Gao W. Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside. Biomarkers Biochem Indic Expo Response Susceptibility Chem 2011; 16: 466-75.
9. [9]. Unsicker K, Spittau B, Krieglstein K. The multiple facets of the TGF-β family cytokine growth/differentiation factor- 15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev 2013; 24: 373-84.
10. [10]. Kempf T, Eden M, Strelau J, et al. The transforming growth factorbeta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006; 98: 351-60.
11. [11]. Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 1054-60.
12. [12]. Lok DJ, Klip IT, Lok SI, et al. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am J Cardiol 2013; 112: 831-7.
13. [13]. Daniels LB, Clopton P, Laughlin GA, et al. Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation 2011; 123: 2101-10.
14. [14]. Khan SQ, Ng K, Dhillon O, et al. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J 2009; 30: 1057-65.
15. [15]. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P. Relation of growth-differentiation factor 15 to left ventricular remodeling in ST-segment elevation myocardial infarction. Am J Cardiol 2011; 108: 955-8.
16. [16]. Anand IS, Kempf T, Rector TS, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 2010; 122: 1387-95.
17. [17]. Izumiya Y, Hanatani S, Kimura Y, et al. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. Can J Cardiol 2014; 30: 338-44.
18. [18]. Brown DA, Breit SN, Buring J, et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet 2002; 359: 2159-63.
19. [19]. Eggers KM, Kempf T, Wallentin L, et al. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. Clin Chem 2013; 59: 1091-8.
20. [20]. Brown DA, Ward RL, Buckhaults P, et al. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res 2003; 9: 2642-50.
21. [21]. Koopmann J, Buckhaults P, Brown DA, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res Off J Am Assoc Cancer Res 2004; 10: 2386-92.
22. [22]. Lee DH, Yang Y, Lee SJ, et al. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 2003; 63: 4648-55.
23. [23]. Shnaper S, Desbaillets I, Brown DA, et al. Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int J Cancer J Int Cancer 2009; 125: 2624-30.
24. [24]. Welsh JB, Sapinoso LM, Kern SG, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 2003; 100: 3410-5.
25. [25]. Lok SI, Winkens B, Goldschmeding R, et al. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail 2012; 14: 1249-56.
26. [26]. Wang J, Xu N, Feng X, et al. Targeted disruption of Smad4 in cardiomyocytes results incardiac hypertrophy and heart failure. Circ Res 2005; 97: 821-8.
27. [27]. Yang H, Filipovic Z, Brown D, et al. Macrophage inhibitory cytokine- 1: a novel biomarker for p53 pathway activation. Mol Cancer Ther 2003; 2: 1023-9.
28. [28]. Breit SN, Johnen H, Cook AD, et al. The TGF-beta superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 2011; 29: 187-95.
29. [29]. Wallentin L, Zethelius B, Berglund L, et al. GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men. PLoS One 2013;.2: 8.
30. [30]. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001; 37: 379-85.
31. [31]. Wang TJ, Larson MG, Levy D, et al. Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and Death. N Engl J Med 2004; 350: 655-63.
32. [32]. Bruins S, Fokkema MR, Römer JWP, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004; 50: 2052-8.
33. [33]. Peeters JMPWU, Sanders-van Wijk S, Bektas S, et al. Biomarkers in outpatient heart failure management; Are they correlated to and do they influence clinical judgment? Neth Heart J Mon J Neth Soc Cardiol Neth Heart Found 2014; 22: 115-21.
34. [34]. Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012; 126: 1596-604.
35. [35]. Richter B, Koller L, Hohensinner PJ, et al. A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. Int J Cardiol 2013; 168: 1251-7.
36. [36]. Bonaca MP, Morrow DA, Braunwald E, et al. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 2011; 31: 203-10.
37. [37]. Wang F, Guo Y, Yu H, et al. Growth differentiation factor 15 in different stages of heart failure: potential screening implications. Biomark Biochem Indic Expo Response Susceptibility Chem 2010; 15: 671-6.
38. [38]. Lind L, Wallentin L, Kempf T, et al. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J 2009;30: 2346-53.
39. [39]. Santhanakrishnan R, Chong JPC, Ng TP, et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal probrain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 2012; 14: 1338-47.
40. [40]. Dinh W, Füth R, Lankisch M, et al. Growth-differentiation factor-15: a novel biomarker in patients with diastolic dysfunction? Arq Bras Cardiol 2011; 97: 65-75.
41. [41]. Stahrenberg R, Edelmann F, Mende M, et al. The novel biomarker growth differentiation factor- 15 in heart failure with normal ejection fraction. Eur J Heart Fail 2010; 12: 1309-16.
42. [42]. Gaggin HK, Szymonifka J, Bharadwaj A, et al. Head-to-Head Comparison of Serial Soluble ST2, Growth Differentiation Factor-15, and Highly-Sensitive Troponin T Measurements in Patients With Chronic Heart Failure. J Am Coll Cardiol HF 2014; 2: 65-72.
43. [43]. Lin JF, Wu S, Hsu SY, et al. Growth-Differentiation Factor-15 and Major Cardiac Events. Am J Med Sci 2014; 347; 305-11.
44. Xanthakis V, Larson MG, Wollert KC, et al. Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. J Am Heart Assoc 2013; 2: e000399.